BiondVax Pharma Rebrands as Scinai Immunotherapeutics to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
$BVXV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices.
The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorrow.